Poor
Partially Aligned
Patient Risk:
Low
Summary
Only one medical/usage claim (COPD maintenance indication) is supported by the provided label excerpts. Several other claims concern discontinuation/market withdrawal and alternative branded therapies, none of which are addressed in the provided prescribing information excerpts, making them unsupported for label-alignment purposes. No dosing/contraindication/boxed-warning/safety/drug-interaction claims were accurately evaluated beyond the indication.
Category Scores
Accurate Statements
Tudorza Pressair is an inhaled medication used for the long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
INDICATIONS AND USAGE: indicated for the maintenance treatment of patients with COPD (maintenance treatment of COPD).
Unsupported Statements
Tudorza Pressair was discontinued by its manufacturer, AstraZeneca.
Not supported by the provided FDA label excerpts (no labeling statements about discontinuation).
AstraZeneca announced the discontinuation of Tudorza Pressair in the United States.
Not supported by the provided FDA label excerpts.
Tudorza Pressair was removed from the market in the United States.
Not supported by the provided FDA label excerpts.
AstraZeneca has not publicly detailed the specific reasons behind the discontinuation of Tudorza Pressair.
Not supported by the provided FDA label excerpts.
Following the manufacturer's decision, Tudorza Pressair is no longer available for prescription or purchase in the United States.
Not supported by the provided FDA label excerpts.
Alternative COPD treatments include other inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs).
The provided label excerpts do not discuss alternative therapies or specific drug classes as alternatives.
Alternative COPD treatments include combination therapies.
The provided label excerpts do not discuss alternative therapies or combination therapies.
AstraZeneca offers Symbicort (budesonide/formoterol fumarate dihydrate), which is used to manage COPD.
Not supported by the provided FDA label excerpts for Tudorza Pressair; no label content provided about Symbicort or its COPD use.
AstraZeneca offers Daliresp (roflumilast), which is used to manage COPD.
Not supported by the provided FDA label excerpts for Tudorza Pressair; no label content provided about Daliresp or its COPD use.
Contradictions
Important Omissions
For any claim about use context (e.g., safety/usability beyond maintenance treatment), the label excerpt specifies key limitations such as not for acute use (rescue therapy) and precautions (e.g., paradoxical bronchospasm, glaucoma, urinary retention, hypersensitivity). None of the provided claims addressed these points, so no safety/context clarifications were included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported medical claim is the COPD maintenance indication. Other claims are about discontinuation/market availability and alternatives and are not derived from label safety information provided; therefore they do not directly establish incorrect dosing or contraindicated use within the label evaluation scope.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims (manufacturer discontinuation/market withdrawal and alternative branded therapies) are not supported by the provided FDA prescribing information excerpts.
Suggested Improvement
Limit statements to those explicitly supported by the provided label excerpts (e.g., maintenance treatment indication) and avoid asserting discontinuation/availability or naming alternative products/uses unless supported by label text provided for those specific topics.